The earnings call highlighted strong revenue growth, a solid financial position, and significant progress in clinical trials, despite increased expenses and a regulatory setback. The company's expansion in the U.S. and consistent profitability were notable achievements. However, delays in revenue recognition and increased operational costs posed challenges.

Company Guidance

During CLINUVEL's investor webinar, several key financial metrics and operational highlights for the fiscal year ending June 30, 2025, were discussed. The company reported a 10% increase in revenue, reaching $105 million, driven by a 6% growth in commercial sales in the U.S. and Europe. Sales reimbursements grew by 24%, and U.S. expansion was bolstered by 104 trained and accredited sites, aiming for 120 by year-end. Interest income from term deposits rose by 29%, despite a 20% increase in expenses, which focused on reinvestment in R&D and employee development. Notable achievements included a ninth consecutive annual profit, an eighth consecutive annual dividend, and a 22% increase in cash reserves. The company's net tangible asset backing rose by 19%, with a net profit margin of 34% and a 35% revenue CAGR over nine years. Additionally, CLINUVEL remained debt-free for the 20th consecutive year, with significant cash reserves providing a strong operational buffer. The company also highlighted its ongoing clinical trials and expansion efforts, including the fully recruited Phase III CUV105 vitiligo trial.

Record Revenue Growth

Revenues increased by 10% to $105 million, breaking the $100 million barrier for the first time. This included a 6% growth in commercial sales and a 24% growth in sales reimbursements, primarily driven by expansion in the U.S. and Europe.

Strong Financial Position

Cash reserves increased by 22%, and the company remains debt-free for the 20th consecutive year. Net tangible asset backing increased by 19%, and a 5% dividend was declared.

Clinical Advancements

CUV105 vitiligo clinical trial is fully recruited. The company is advancing trials in vitiligo, expanding the adult EPP market, and finalizing the manufacturing of the ACTH generic product.

Expansion in the U.S.

The number of trained and accredited sites in North America increased to 104, with a target of 120 sites by the end of the calendar year.

Consistent Profitability

Achieved the ninth consecutive annual profit and declared the eighth consecutive annual dividend, the fourth of which is fully franked.

Clinuvel Pharmaceuticals (CLVLF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLVLF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 24, 2026	2026 (Q2)	0.17 / -	0.183	―	―	―
Aug 27, 2025	2025 (Q4)	0.18 / 0.29	0.323	-11.13% (-0.04)
Feb 26, 2025	2025 (Q2)	0.14 / 0.18	0.139	32.08% (+0.04)
Aug 29, 2024	2024 (Q4)	0.29 / 0.32	0.248	30.34% (+0.08)
Feb 21, 2024	2024 (Q2)	0.17 / 0.14	0.144	-3.64% (>-0.01)	―
Aug 29, 2023	2023 (Q4)	0.24 / 0.25	0.199	24.67% (+0.05)	―
Feb 22, 2023	2023 (Q2)	0.20 / 0.14	0.075	92.98% (+0.07)	―	―
Aug 30, 2022	2022 (Q4)	0.20 / 0.20	0.233	-14.85% (-0.03)	―	―
Feb 22, 2022	2022 (Q2)	0.15 / 0.07	0.083	-10.24% (>-0.01)	―	―
Aug 26, 2021	2021 (Q4)	- / 0.23	0.207	12.97% (+0.03)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLVLF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 27, 2025	$8.46	$8.13	-3.90%
Feb 26, 2025	$6.92	$6.92	0.00%
Aug 29, 2024	$9.33	$10.35	+10.93%
Feb 21, 2024	$10.47	$9.77	-6.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Clinuvel Pharmaceuticals Limited (CLVLF) report earnings?

Clinuvel Pharmaceuticals Limited (CLVLF) is schdueled to report earning on Feb 24, 2026, TBA (Confirmed).

What is Clinuvel Pharmaceuticals Limited (CLVLF) earnings time?

Clinuvel Pharmaceuticals Limited (CLVLF) earnings time is at Feb 24, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CLVLF EPS forecast?

CLVLF EPS forecast for the fiscal quarter 2026 (Q2) is 0.17.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing